RxDoctor Payments Data

Melinda Wolfe, APRN

Psychiatric/Mental Health · Concord, NHNPI 1902915036

Payments from drug & device makers

$746in general payments, 2019–2025

Across 22 payments — averaging $33.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$288
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$101
  • Axsome Therapeutics, Inc.$95
  • Alkermes, Inc.$87
  • Otsuka America Pharmaceutical, Inc.$52
  • Novo Nordisk$50
  • plus $72 from 3 others

What the payments were for

  • Food & beverage$746100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$746 in reported general payments places this provider in the 60th percentile of 264 psychiatric/mental health providers in New Hampshire.

See all psychiatric/mental health providers in New Hampshire

Medicare billing

Part B allowed, 2024
$21,433
Medicare patients
36
Services billed
243

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole13$18,135
VyvanseLisdexamfetamine Dimesylate12$4,543
Lisdexamfetamine Dimesylate11$3,687
Divalproex Sodium ErDivalproex Sodium20$1,780
Quetiapine Fumarate ErQuetiapine Fumarate19$1,565
Vilazodone Hcl15$1,473
Duloxetine Hcl74$1,375
Asenapine Maleate11$1,303
Venlafaxine Hcl ErVenlafaxine Hcl40$961
Lamotrigine83$850
Quetiapine Fumarate42$823
Buspirone Hcl20$792
Bupropion XlBupropion Hcl44$772
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine43$621
Mirtazapine23$592

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$52$18,13513 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$26$4,54312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 264 psychiatric/mental health providers in New Hampshire.

Other psychiatric/mental health in Concord

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →